ID: ALA74343

Max Phase: Preclinical

Molecular Formula: C19H30N4O8S

Molecular Weight: 474.54

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC[C@H](C)CC(=O)NS(=O)(=O)CC(=O)N[C@]1(C(=O)O)[C@@H]2CN(C)C=C(C(N)=O)[C@@H]2C[C@@H]1O

Standard InChI:  InChI=1S/C19H30N4O8S/c1-4-10(2)5-15(25)22-32(30,31)9-16(26)21-19(18(28)29)13-8-23(3)7-12(17(20)27)11(13)6-14(19)24/h7,10-11,13-14,24H,4-6,8-9H2,1-3H3,(H2,20,27)(H,21,26)(H,22,25)(H,28,29)/t10-,11-,13+,14-,19+/m0/s1

Standard InChI Key:  BMZQWZIGQOMHQM-ROKCGPLXSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 474.54

Molecular Weight (Monoisotopic): 474.1784

AlogP: -1.88

#Rotatable Bonds: 9

Polar Surface Area: 196.20

Molecular Species: ACID

HBA: 8

HBD: 5

#RO5 Violations: 0

HBA (Lipinski): 12

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.16

CX Basic pKa: 0.27

CX LogP: -2.20

CX LogD: -6.58

Aromatic Rings: 0

Heavy Atoms: 32

QED Weighted: 0.25

Np Likeness Score: 0.27

References

1. Banwell MG, Crasto CF, Easton CJ, Forrest AK, Karoli T, March DR, Mensah L, Nairn MR, O'Hanlon PJ, Oldham MD, Yue W..  (2000)  Analogues of SB-203207 as inhibitors of tRNA synthetases.,  10  (20): [PMID:11055334] [10.1016/s0960-894x(00)00456-x]

Source

Source(1):

• Scientific Literature